Ventricular Tachycardia Ablation Through Radiation Therapy Consortium: Concept Description of an Observational Retrospective Multicentric Trial
A legfontosabb adatok
- Ki végzi
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Hol
- Olaszország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Résztvevők
- 149 fő vett részt
- Kezdés
- 2025. márc. 30.
- Várható befejezés
- 2029. márc. 30.
- A vizsgálat típusa
- Megfigyeléses, 2 csoport
- A regiszteradat frissítve
- 2025. május 25.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 10 feltétel megnézéseKevesebb
Ki vehet részt
- Diagnosis of refractory ventricular tachycardia (VT), as previously defined
- Age greater than 18 years
- Presence of an implantable cardioverter-defibrillator (ICD) for follow-up
- Not eligible for heart transplantation
- Estimated life expectancy of at least 1 year
- Ability to provide autonomous, informed consent to participate in the study
Ki nem vehet részt
- Patients with active neoplastic disease under oncological treatment
- ICD interrogation demonstrating polymorphic VT
- Patients with INTERMACS class more than 4
- Patients with LVADs
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Recurrent ventricular tachycardia (VT) is a potentially life-threatening arrhythmia in patients with structural heart disease. Despite the use of antiarrhythmic drugs, implantable cardioverter-defibrillators (ICDs), and radiofrequency catheter ablation, VT recurrence rates remain high-reaching up to 66% in some series. For patients with refractory VT who are not candidates for further ablation or surgical interventions, there is a significant unmet need for novel, effective, and non-invasive treatment options.
A teljes eredeti leírásKevesebb
Stereotactic body radiation therapy (SBRT) has recently emerged as a promising approach for treating ventricular arrhythmias through a technique known as stereotactic arrhythmia radioablation (STAR). Preliminary studies, including a phase I/II clinical trial, have demonstrated a substantial reduction in VT burden-up to 99.9%-following treatment, with an acceptable safety profile. Reported adverse events have included manageable pericardial effusion, radiation-induced pericarditis, and pneumonitis. The growing body of evidence supports STAR as a feasible and effective alternative for selected patients with treatment-resistant VT.
The objective of this study is to evaluate the efficacy and safety of stereotactic radiotherapy as a non-invasive ablation technique for the treatment of ventricular tachycardia (VT) in patients with refractory arrhythmias in whom conventional therapies have failed.
This is a retrospective observational study aimed at comparing outcomes between patients who received stereotactic radioablation and those who did not. A matched-pair analysis will be used to adjust for baseline clinical characteristics and ensure comparability between groups.
A vizsgálat 2 csoportja
- patients who have undergone SBRT
Within this group we find patients who have had all possible canonical treatments for the arrhythmia and also the stereotactic radiation treatment
- patients who have not undergone SBRT
Within this group we find patients who have had all possible canonical treatments for the arrhythmia, but not the stereotactic radiation treatment
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Ventricular Tachycardia Ablation Through Radiation Therapy Consortium: Concept Description of an Observational Retrospective Multicentric Trial Via Matched Pair Analysis (VT-ARTr)
- A regiszteradat frissítve
- 2025. május 25.